2m 2m 2m 2m 2m 2m 2m
ALAUNOS (TCRT)
NASDAQ
$2.97-$0.12 (-3.73%)
Price as of Oct 22, 2026 7:59 PM EDT- $7.8MMarket Cap
- 20.31%1-Year Change
- BiotechnologyIndustry
ALAUNOS (TCRT)
$2.97-$0.12 (-3.73%)
Key Performance
More- Earnings Score: N/A
- Momentum Score: 29
- True Yield: N/A
- Financial Health Score: N/A
Latest Research & News
No data found
Peers
Statistics
MoreDay Range
$2.81
$3.33
$3.08
1-Year Range
$0.74
$4.36
$3.08
Latest Close$3.08
Change
+$0.11 (+3.57%)
Volume2,603,803
Market Cap$7.8M
Shares Outstanding2.5M
P/E (TTM)-1.71
Diluted EPS (TTM)-$1.81
Enterprise Value$7.7M
Information as of 10/21/2026
Company Profile
ALAUNOS THERAPEUTICS INC
https://www.alaunos.com$7.8M
Market Cap
-$4.0M
Net Income
Sector: Healthcare
Industry: Biotechnology
501 E. Las Olas Blvd., Fort Lauderdale, FL, United States, 33301
346 355 4099Alaunos Therapeutics, Inc., a pre-clinical stage biopharmaceutical company that develops orally administered small-molecule therapeutics for the treatment of obesity and related metabolic disorders. It develops non-hormonal, non-incretin approach, and unlike hormone-based treatments, such as GLP-1 drugs. The company also develops hunTR TCR discovery platform to target driver mutations. Alaunos Therapeutics, Inc. was founded in 2003 and is based in Fort Lauderdale, Florida.
Key Executives
- Holger Weis
- Ferdinand Groenewald
Current Ownership Distribution
- Institutions572.1M (76.70%)
- Mutual Funds168.0M (22.52%)
- Insiders5.7M (0.77%)
- Other0 (0.00%)